IN2012DN01234A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01234A
IN2012DN01234A IN1234DEN2012A IN2012DN01234A IN 2012DN01234 A IN2012DN01234 A IN 2012DN01234A IN 1234DEN2012 A IN1234DEN2012 A IN 1234DEN2012A IN 2012DN01234 A IN2012DN01234 A IN 2012DN01234A
Authority
IN
India
Prior art keywords
compounds
formula
well
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
Inventor
Gregory Martin Benson
Konrad Bleicher
Song Feng
Uwe Grether
Bernd Kuhn
Rainer E Martin
Jean-Marc Plancher
Hans Richter
Markus Rudolph
Sven Taylor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN01234A publication Critical patent/IN2012DN01234A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A, B, R1, R2, R3, R4, R5, n, m and p have the significance given in claim 1.
IN1234DEN2012 2009-09-29 2010-09-27 IN2012DN01234A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171700 2009-09-29
PCT/EP2010/064217 WO2011039130A1 (en) 2009-09-29 2010-09-27 New benzimidazole derivatives and their use as fxr agonists

Publications (1)

Publication Number Publication Date
IN2012DN01234A true IN2012DN01234A (en) 2015-05-15

Family

ID=43033176

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1234DEN2012 IN2012DN01234A (en) 2009-09-29 2010-09-27

Country Status (12)

Country Link
US (1) US8309581B2 (en)
EP (1) EP2483247A1 (en)
JP (1) JP5503007B2 (en)
KR (1) KR101477872B1 (en)
CN (1) CN102574812B (en)
AU (1) AU2010303146A1 (en)
BR (1) BR112012006986A2 (en)
CA (1) CA2772815A1 (en)
IL (1) IL218037A0 (en)
IN (1) IN2012DN01234A (en)
MX (1) MX2012002479A (en)
WO (1) WO2011039130A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377523B (en) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION.
CN108072684B (en) * 2016-11-11 2020-06-16 中国科学院广州生物医药与健康研究院 Novel ligand of farnesoid X receptor and screening method and application thereof
KR20190117632A (en) 2017-02-21 2019-10-16 장피트 Combination of PPAR agonist and FXR agonist
EP3600293A1 (en) 2017-03-30 2020-02-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888847B1 (en) * 2005-07-22 2007-08-31 Sanofi Aventis Sa N- (HETERIARYL) -1-HETEORARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION
WO2008000643A1 (en) 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same
DE102007008420A1 (en) 2007-02-21 2008-08-28 Merck Patent Gmbh benzimidazole derivatives
KR101237577B1 (en) * 2007-08-27 2013-02-26 에프. 호프만-라 로슈 아게 Benzimidazole derivatives used as fxr agonists
MX2010005164A (en) * 2007-11-15 2010-05-27 Hoffmann La Roche Novel methyl-benzimidazole derivatives.
ES2407180T3 (en) * 2008-09-11 2013-06-12 F. Hoffmann-La Roche Ag New benzimidazole derivatives
CA2738872A1 (en) * 2008-10-15 2010-04-22 F. Hoffmann-La Roche Ag New benzimidazole derivatives

Also Published As

Publication number Publication date
HK1171746A1 (en) 2013-04-05
MX2012002479A (en) 2012-03-26
KR20120063536A (en) 2012-06-15
CA2772815A1 (en) 2011-04-07
BR112012006986A2 (en) 2016-04-12
AU2010303146A1 (en) 2012-04-19
JP2013505977A (en) 2013-02-21
EP2483247A1 (en) 2012-08-08
US8309581B2 (en) 2012-11-13
JP5503007B2 (en) 2014-05-28
WO2011039130A1 (en) 2011-04-07
US20110077273A1 (en) 2011-03-31
CN102574812B (en) 2016-03-30
CN102574812A (en) 2012-07-11
IL218037A0 (en) 2012-04-30
KR101477872B1 (en) 2014-12-30

Similar Documents

Publication Publication Date Title
IN2012DN03337A (en)
MX2010005824A (en) Aminothiazole derivatives.
MY138941A (en) Aryl-pyridine derivatives
MX2011012017A (en) Azacyclic spiroderivatives as hsl inhibitors.
TW200738241A (en) Pyridazine derivatives
UA102310C2 (en) Heterocyclic sufonamides, use thereof and pharmaceuticsl compositions
GEP20125487B (en) Organic compounds and their use
IN2012DN01232A (en)
TW200745032A (en) Novel heterobicyclic derivatives
MX2009004441A (en) Indazole derivatives useful as l-cpt1 inhibitors.
TW200626558A (en) Indazolone derivatives
MX2009010218A (en) Aza-pyridopyrimidinone derivatives.
TW200740764A (en) Pyrazolone derivatives
PH12013500942A1 (en) Triazolopyridine compounds
PH12012502335A1 (en) Nitrogen containing heteroaryl compounds
TW200833324A (en) Sulfonamide derivatives
MX2012007536A (en) Nitrogen-containing heteroaryl derivatives.
IN2012DN00765A (en)
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
MX2010005714A (en) Pyridine compounds.
MX2008016426A (en) Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1).
MX2010001742A (en) Novel piperazine amide derivatives.
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
GEP201606545B (en) 2-piperazin-1-yl-4h-1,3-benzo-thiazin-4-one derivatives and their use for treatment of mammalian infections
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents